Company Overview and News
TOMAKOMAI – A test site in Japan for burying carbon dioxide (CO2) below the seabed off Hokkaido is showing more promise than other carbon, capture and storage (CCS) projects by cutting costs and increasing efficiency, its developer says.
The Southern Company (SO - Free Report) recently announced a 3.4% hike in its quarterly dividend, resulting in the company paying a quarterly dividend of 60 cents per share compared with 58 cents paid earlier. Shareholders of Southern Company of record as of May 21, 2018 will now be rewarded with the increased dividend on Jun 6, 2018, which is in line with our expectations.
The last few weeks haven’t exactly been that great for investors. Thanks to a variety of factors, volatility has returned with a vengeance and we’ve actually seen some big intraday price swings and declines. In fact, the S&P 500 is barely positive on the year and is more than 6% below its peak reached at the end of January. And that decline has hit all matter of equities.
Let’s take a look at Southern Company’s payout ratio. A payout ratio indicates a portion of a company’s profits distributed to shareholders in the form of dividends. In 2017, Southern Company’s payout ratio was 76%. We’ve adjusted SO’s earnings for extraordinary items, which included a $3.4 billion loss on the Kemper County power plant in 2017.
Although Southern Company’s (SO) dividend yield is higher than many of its peers, it significantly lags behind its peers in terms of dividend growth. Its dividends per share grew 3.4% compounded annually in the last five years. In comparison, the broader utilities (XLU) increased their dividends per share by 4% compounded annually in the same period.
Georgia-based Southern Company (SO) announced on April 16, 2018, that it has raised its quarterly dividend by $0.02 to $0.60 per share. In 2018, it’s expected to pay $2.38 per share, which is more than 3% higher than its total dividends per share last year. The ex-dividend date is May 18, 2018, and the dividend will be paid on June 6, 2018.
Southern Company (SO) expects to increase its earnings per share by 4%–6% annually for the next few years, which is in line with the industry average. The utility’s huge exposure to regulated operations is likely to facilitate stable earnings going forward, which could ultimately support its targeted dividend growth for the next few years. Its gas operations witnessed huge growth in 2017 due to its AGL Resources acquisition.
Some might ask, why are you investing so prudently now? Most investors say they want to build the biggest nest egg they can to fund the best possible retirement when that time comes. Once that day arrives, then they’ll change their portfolio to focus less on growth and more on income.
US utility stocks have been sluggish for the last few months. Utilities that are sensitive to the interest rate have been on a downward streak since December 2017 mainly due to tax reforms, rate hikes, and valuation concerns. Utilities continued their downtrend last week. The Utilities Select Sector SPDR ETF (XLU) fell more than 1%, while broader markets rose more than 2% during the week.
* SOUTHERN CO - ON APRIL 16, , APPOINTED ANDREW W. EVANS, TO SERVE AS EXECUTIVE VP AND CFO OF SOUTHERN COMPANY, EFFECTIVE JUNE 1, 2018 - SEC FILING
Document UNITED STATES SECURITI
Electric utility firm The Southern Company (SO - Free Report) traditionally makes an announcement to up its payout at this time of year.
Sempra Energy (SRE), one of the leading utilities in California, declared a dividend of $0.90 per share in 1Q18, which represented a 9% increase over the previous quarter. This was Sempra Energy’s eighth consecutive annual per-share dividend increase.
Tired of keeping a close eye on financial news and popping in and out of positions in an effort to get the most out of an increasingly volatile market?
I also like to buy stocks of companies that meet several of my criteria and are currently selling for a fair price.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET